James Christensen - Mirati Ther Chief Scientific Officer and Sr. VP
SVP
Dr. James G. Christensen, Ph.D. is the Executive Vice President, Chief Scientific Officer of Mirati Therapeutics Inc. Prior to joining us, he held various positions at Pfizer from 2003 to 2013, the most recent of which was Senior Director of Oncology Precision Medicine in the Oncology Research Unit. While Dr. Christensen joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib malate research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib. Dr. Christensen participated as a member of the Cancer Research or Oncology Research Unit leadership team from 2005 to 2013. Prior to 2003, Dr Christensen was a Group Leader on the Preclinical Research and Exploratory Development team at SUGEN, Inc., which was acquired by Pharmacia Corporationrationration, now owned by Pfizer. Dr. Christensen began his career in 1998 at Warner Lambert, now owned by Pfizer, with research focus in RTK biology and RTK pathway biomarker development in the oncology therapeutic area. Dr. Christensen participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics since 2018.
| Age | 56 |
| Tenure | 7 years |
| Phone | 858 332 3410 |
| Web | https://www.mirati.com |
Mirati Ther Management Efficiency
The company has return on total asset (ROA) of (0.393) % which means that it has lost $0.393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6995) %, meaning that it created substantial loss on money invested by shareholders. Mirati Ther's management efficiency ratios could be used to measure how well Mirati Ther manages its routine affairs as well as how well it operates its assets and liabilities.Mirati Ther currently holds 51.51 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Mirati Ther has a current ratio of 9.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mirati Ther's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | SVP Age | ||
| Justin Drinkwine | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 |
Mirati Ther Leadership Team
Elected by the shareholders, the Mirati Ther's board of directors comprises two types of representatives: Mirati Ther inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mirati. The board's role is to monitor Mirati Ther's management team and ensure that shareholders' interests are well served. Mirati Ther's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mirati Ther's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Benjamin MBA, Chief Officer | ||
| Michael Paolucci, Chief Officer | ||
| Alan MD, Ex Officer | ||
| James Christensen, Chief Scientific Officer and Sr. VP | ||
| Kelly Covello, VP Affairs | ||
| Ryan Asay, VP Affairs | ||
| Laurie Stelzer, Chief Officer | ||
| Reena Desai, Chief Sec | ||
| David Meek, CEO Director |
Mirati Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mirati Ther a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (10.49) % | |||
| Current Valuation | 3.19 B | |||
| Shares Outstanding | 70.15 M | |||
| Shares Owned By Insiders | 1.72 % | |||
| Shares Owned By Institutions | 98.28 % | |||
| Number Of Shares Shorted | 4.39 M | |||
| Price To Earning | (3.97) X | |||
| Price To Book | 4.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Mirati Stock
If you are still planning to invest in Mirati Ther check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mirati Ther's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |